CareRx Reports Results for the Third Quarter of 2025

Core Insights - CareRx Corporation reported strong financial results for Q3 2025, showcasing growth in revenue, EBITDA margins, and bed count, indicating effective operational execution and strategic investments [4][7][15] Financial Performance - Revenue for Q3 2025 reached $93.2 million, an increase from $91.4 million in Q2 2025 and $92.8 million in Q3 2024 [7][9] - Adjusted EBITDA rose to $8.3 million in Q3 2025, compared to $8.0 million in the previous quarter and $7.8 million in Q3 2024 [7][9] - Adjusted EBITDA margin improved to 9.0%, up from 8.8% in Q2 2025 and 8.4% in Q3 2024 [7][9] - Average beds serviced increased to 91,298, reflecting a growth of 1,250 beds from Q2 2025 and 2,199 beds from Q3 2024 [7][15] Notable Events - CareRx declared a quarterly dividend of $0.02 per common share on September 15, 2025, which was paid on October 15, 2025 [8] - The company renewed its normal course issuer bid, allowing for the repurchase of up to 1,500,000 common shares, with 194,100 shares repurchased at an average price of $3.56 per share since the program's commencement [8] - The company hosted Ontario's Minister of Long-Term Care to showcase its innovative pharmacy services and technology [8]